Comparative Pharmacology
Head-to-head clinical analysis: ALPROSTADIL versus XALATAN.
Head-to-head clinical analysis: ALPROSTADIL versus XALATAN.
ALPROSTADIL vs XALATAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular cAMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderateAlprostadil + Limaprost
"Alprostadil may increase the antiplatelet activities of Limaprost."
Clinical Note
moderateAlprostadil + Epoprostenol
"Alprostadil may increase the antiplatelet activities of Epoprostenol."
Clinical Note
moderateTiaprofenic acid + Alprostadil
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Alprostadil
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Carprofen."